相关实验视频

Updated: Feb 28, 2026

Cerenkov Luminescence Imaging CLI for Cancer Therapy Monitoring

Cerenkov Luminescence Imaging CLI for Cancer Therapy Monitoring

Published on: November 13, 2012

对于DLBCL的化学免疫治疗后PET扫描阳性的持久性

James O Armitage¹, Matthew A Lunning², Julie M Vose¹

¹University of Nebraska Medical Center, Omaha, Nebraska, United States.

|February 26, 2026

概括

阳位子发射断层扫描 (PET) 扫描可以高估扩散大B细胞淋巴瘤的治疗反应. 敏感的循环瘤DNA测试可以帮助识别不太可能复发的患者,避免不必要的治疗.

科学领域:

在瘤学瘤学.
核医学是一种核医学.
分子诊断学分子诊断

背景情况:

化学免疫疗法在分散型大B细胞淋巴瘤 (DLBCL) 中产生高响应率,通过PET扫描进行评估.
在PET扫描中具有非代谢性完整反应的患者中,很大一部分患者不会复发.
假阳性PET扫描 (Deauville 4分) 可能导致不必要的,可能有害的干预.

研究的目的:

评估循环瘤DNA (ctDNA) 在区分真正残留疾病的DLBCL患者与假阳性PET扫描患者的有用性.
为了确定可改进DLBCL患者治疗后预后的生物标志物.
为了减少DLBCL患者的过度治疗,非特异性PET异常.

主要方法:

化学免疫治疗后DLBCL患者ctDNA水平的分析.
ctDNA测量与临床结果的相关性,包括复发.
与PET扫描结果 (Deauville分数) 的ctDNA灵敏度和特异性的比较.

主要成果:

ctDNA水平显示有潜力区分残留淋巴瘤患者与假阳性PET扫描患者.
高ctDNA水平可能表明复发的风险更高,即使在PET上看似完全的代谢反应.
非淋巴瘤的疾病可能会导致异常的PET扫描,需要考虑替代诊断.

结论:

敏感的ctDNA测量为改善DLBCL患者化学免疫治疗后风险分层提供了有希望的工具.
在假阳性PET扫描的患者中,ctDNA分析可以帮助避免激进的治疗.
将ctDNA与PET成像进行整合可能会优化治疗决策并减少对患者的伤害.

更多相关视频

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Published on: September 25, 2018

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

相关概念视频

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...